Enhance efferocytosis capacity of dendritic cells for diabetic wound healing by nanozyme-loaded nanofiber dressings

Improving efferocytosis of dendritic cells (DCs) by inhibiting membrane transporter protein SLC7A11 has been explored for healing diabetes wounds. However, the administration of SLC7A11 inhibitors has been linked to the generation of reactive oxygen species (ROS), which may compromise the viability and functionality of DCs. To mitigate this adverse effect, a nanozyme-loaded nanofiber dressing, termed GIPH, was developed. This dressing encapsulates a specific SLC7A11 inhibitor (HG106) in the core layer and incorporates an efficient nanozyme, Ir NPs-PVP, in the shell layer. The Ir NPs-PVP nanozyme effectively neutralizes ROS produced by HG106, thereby enhancing the viability of DCs and further promoting their efferocytosis. Our in vitro experiment results demonstrated that GIPH-treated Bone Marrow-Derived Dendritic Cells (BMDCs) exhibited a 1.68-fold increase in survival and a 1.52-fold enhancement in efferocytosis rate compared to those treated with HG106 alone. Furthermore, in a diabetic mouse wound model, the GIPH group showed superior healing outcomes, with wound nearly achieving complete recovery by day 12 (97.5 %). This research highlights the therapeutic potential of nanozyme-loaded nanofiber dressings while providing valuable insights for future investigations into the DCs-mediated wound healing process.